Results 101 to 110 of about 229,521 (146)
, 2020 Graves' ophthalmopathy is an autoimmune condition characterized by T cell infiltration of the retrobulbar ...
K Trieb +5 more
core
Plasma exchange therapy for severe graves' ophthalmopathy
, 1986 In the present studies, the authors report on the treatment of nine Graves' disease patients with severe ophthalmopathy by use of intensive plasma exchange followed by immunosuppression (during three to six months). Results of treatment were evaluated by
Winand, René +2 more
core +1 more source
Steroid Treatment Focused Management of Graves’ Ophthalmopathy
Acta Medica BulgaricaGraves' disease (GD) is an autoimmune disease that affects the thyroid and the eyes. Graves' ophthalmopathy (GO), an autoimmune disease, usually appears 18 months after GD diagnosis.
Condeng Y. H. +5 more
doaj +1 more source
, 1996 An increased accumulation of glycosaminoglycans (GAGs) in retrobulbar tissues has been reported in patients with Graves' ophthalmopathy (GO). We examined quantitative urinary GAGs excretion in patients with different grades of GO. 36 patients with Graves'
Ademoglu, Evin +4 more
core
Graves\u27 Ophthalmopathy Following HTLV-I Infection
, 2013 After years of diagnosing and following hundreds of patients with Graves\u27 Ophthalmopathy we discovered a young woman who became ill with it within 4 months of converting to a positive HTLV-I antibody titer in routine Blood Bank screening (as a ...
Susan C. Benes
core
Antioxidant agents in the treatment of Graves' ophthalmopathy
, 2000 PURPOSE: To report the effect of antioxidant agents in the treatment of mild and moderately severe Graves' ophthalmopathy. METHODS: Prospective, nonrandomized, comparative study performed at a referral center.
Bouzas, E.A. +3 more
core +1 more source
, 1998 We compared orbital tissue tension and orbital compartment compliance in normal vs Graves\u27 ophthalmopathy ...
Gregory Kosmorsky, DO; C. D. Riemann; J. A. Foster
core
[Biological treatment options for Graves' ophthalmopathy]
, 2008 The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and ...
El Fassi, Daniel +2 more
core
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Treatment of Graves’ ophthalmopathy
Medicina Clínica (English Edition), 2021Graves' ophthalmopathy is an inflammatory disease with primary involvement of the extraocular muscles and the orbit. It encompasses the most common extra-thyroid manifestation in patients with Graves-Basedow disease. The underlying cause is molecular mimicry with the TSH receptor in ocular fibroblasts, leading to an immuno-mediated pathogenesis ...
Andrés, González-García +1 more
openaire +2 more sources
IMMUNOGENETICS OF GRAVES' OPHTHALMOPATHY
Clinical Endocrinology, 1988SUMMARYWe have performed an immunogenetic analysis of 53 patients with severe Graves' ophthalmopathy, 51 patients with Graves' disease but little or no clinically apparent eye disease, and 90 controls. The distribution of restriction fragment length polymorphisms was analysed in the three groups, using probes for the HLA‐DQα and DRβ regions, the T‐cell
Weetman, A. P. +5 more
openaire +3 more sources